 it's it's kind of crazy to me like i i look at sort of the the profile of the company today from market perspective and it's pretty clear investors are missing the message right which is you're talking about this is the beginning of the next regeneron the next pure attack the next ligand and you're seeing your front proceed i would argue though and we don't talk about share price and such on this program but i will tell you your share price has has